Evaluation of the Tolerance, Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of MIL62 Injection for Treating Lupus Nephritis

• Status: ACTIVE_NOT_RECRUITING
• Trial end date: 2025-08-01

Summary

This study is composed of two stages: Part A is a randomized, double-blind, placebo-controlled dose-escalation study (i.e., Phase 1b study). The first part has a total of 3 dose groups, with 10 subjects enrolled in each dose group. Subjects are randomly assigned to receive MIL62 combined with standard of care or placebo combined with standard of care at a 4:1 ratio. Based on the tolerability, safety, pharmacodynamics, pharmacokinetics, and preliminary efficacy of the 3 dose groups, the maximum tolerated dose (MTD), recommended phase 2 dose (RP2D), and dosing frequency will be determined.

Part B is open-label, enrolling 10 subjects who will receive the recommended dose of MIL62 combined with standard of care.

• Phase: PHASE1

Details

• Lead Sponsor: Beijing Mabworks Biotech Co., Ltd.